What was the most successful biotech IPO of 2014?

Look no further than Ultragenyx. A special report by Fierce Biotech says that the Novato, Calif., maker of treatments for rare and ultra-rare diseases took the top spot for the year, raising nearly $122 million in the offering of more than 5.8 million shares.

But Ultragenyx isn’t alone in California, which claims five spots on the top-10 list. Also represented are companies in Massachusetts, Texas and the Netherlands. Here’s a look at the full list:

1. Ultragenyx Pharmaceutical (RARE)

Headquarters: Novato, Calif.
IPO price: $21
Close Sept. 30: $56.60
Change: Up 170%
Raised: $122 million

2. ZS Pharma (ZSPH)

Headquarters: Coppell, Texas
IPO price: $18
Close Sept. 30: $39.23
Change: Up 118%
Raised: $107 million

3. Auspex Pharmaceuticals (ASPX)

Headquarters: La Jolla, Calif.
IPO price: $12
Close Sept. 30: $25.67
Change: Up 114%
Raised: $84 million

4. Avalanche Biotechnologies (AAVL)

Headquarters: Menlo Park, Calif.
IPO price: $17
Close Sept. 30: $34.19
Change: Up 101%
Raised: $102 million

5. Sage Therapeutics (SAGE)

Headquarters: Cambridge, Mass.
IPO price: $18
Close Sept. 30: $31.50
Change: Up 75%
Raised: $90 million

6. Kite Pharma (KITE)

Headquarters: Santa Monica, Calif.
IPO price: $17
Close Sept. 30: $28.50
Change: Up 68%
Raised: $128 million

7. Otonomy (OTIC)

Headquarters: San Diego
IPO price: $16
Close Sept. 30: $24
Change: Up 50%
Raised: $100 million

8. Zafgen (ZFGN)

Headquarters: Boston
IPO price: $16
Close Sept. 30: $19.65
Change: Up 23%
Raised: $102.7 million

9. ProQR Therapeutics (PRQR)

Headquarters: Leiden, Netherlands
IPO price: $13
Close Sept. 30: $17.19
Change: Up 32%
Raised: $98 million

10. Radius Health (RDUS)

Headquarters: Waltham, Mass.
IPO price: $8
Close Sept. 30: $21
Change: Up 163%
Raised: $52 million